Response Oncology (Response Oncology) EPS (Diluted) : $-4.15 (TTM As of Mar. 2002)

Response Oncology EPS (Diluted) Chart

Response Oncology Annual Data
	Trend	Dec92	Dec93	Dec94	Dec95	Dec96	Dec97	Dec98	Dec99	Dec00	Dec01
EPS (Diluted)		Get a 7-Day Free Trial					0.36	-1.45	-0.14	-1.17	-4.18

Response Oncology Quarterly Data
	Jun97	Sep97	Dec97	Mar98	Jun98	Sep98	Dec98	Mar99	Jun99	Sep99	Dec99	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02
EPS (Diluted)	Get a 7-Day Free Trial															-0.10	-0.07	-0.06	-3.95	-0.07

Competitive Comparison of Response Oncology's EPS (Diluted)

For the Medical Care Facilities subindustry, Response Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Oncology's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Response Oncology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Response Oncology's PE Ratio falls into.

Response Oncology EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Response Oncology's Diluted EPS for the fiscal year that ended in Dec. 2001 is calculated as

Response Oncology's Diluted EPS for the quarter that ended in Mar. 2002 is calculated as

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2002 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Oncology  (GREY:ROIX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Response Oncology EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Response Oncology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Oncology (Response Oncology) Business Description